Earnings call transcript: Monash IVF posts FY 2026 profit miss as shares rise

Monash IVF Group reported a FY 2026 underlying net profit after tax of AUD 16.1 million, falling short of the updated guidance range of AUD 17 million to AUD 18 million. Despite the earnings miss, the company's shares rose 2.94% to $0.70, indicating investor confidence in the company's future prospects. Revenue remained relatively stable at AUD 269 million, a decrease of less than 1% compared to the previous year, showcasing the resilience of Monash IVF's customer base.

EBITDA margin narrowed to 19.8%, down from 25.4% in FY 2025, driven by stricter pricing and cost restraint. The domestic market share improved to 20.2% in the second half of FY 2026, an increase of 120 basis points on a rolling six-month basis, while the clinical pregnancy rate for women under 43 increased to 42.1%, up 1.8% from the previous year.

Monash IVF's FY 2027 is expected to bring lower capital spending and a stronger emphasis on productivity and utilization, with capital expenditure anticipated to fall by more than 50%. The company's CEO, Victoria, believes the Australian assisted reproductive services market will return to growth in FY 2027, driven by improved patient registrations and stimulated cycles.

The management is also shifting investor focus from short-term earnings pressure to long-term operating leverage and clinical differentiation.